Categories AlphaGraphs, Consumer, Earnings

JNJ Earnings: Johnson & Johnson Q3 adj. profit drops despite higher sales

Johnson & Johnson (NYSE: JNJ) reported a decline in adjusted profit for the third quarter of 2022, despite a modest increase in net sales. The pharma giant’s shares declined early Tuesday following the announcement.

Johnson & Johnson Q3 2022 earnings infographic

Net sales increased 2% year-over-year to $23.8 billion during the third quarter. The core Consumer products sales remained broadly unchanged from last year, while Pharmaceutical and Medtech sales increased by 3% and 2%, respectively.

Third-quarter adjusted earnings decreased to $2.55 per share from $2.60 per share in the prior-year period. Unadjusted profit was $4.46 billion or $1.68 per share, compared to $3.67 billion or $1.37 per share a year earlier.

Check this space to read management/analysts’ comments on Johnson & Johnson’s Q3 2022 earnings

“Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline,” said Joaquin Duato, chief executive officer of Johnson & Johnson.

Prior Performance

Most Popular

Key takeaways from Cintas’ (CTAS) third-quarter 2023 report

Cintas Corporation (NASDAQ: CTAS) has been growing its market share by diversifying into new areas and through acquisitions. The prudent business model, with a focus on recurring revenues, has helped

Here are a few points to keep in mind if you are considering Starbucks Corporation (SBUX)

Shares of Starbucks Corporation (NASDAQ: SBUX) stayed in green on Thursday. The stock has gained 10% over the past 12 months. The company delivered healthy results for its most recent

ANGO Earnings: AngioDynamics reports loss for Q3; revenue up 9%

AngioDynamics Inc. (NASDAQ: ANGO) on Thursday reported a wider loss for the third quarter when the medical device maker's revenues increased by 9%. The company also provided guidance for fiscal

Add Comment
Viewing Highlight